This is the authors' abstract. We don't add key points for this paper.
Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can be associated with euglycemic diabetic ketoacidosis (eDKA). Severe metabolic acidosis with extreme electrolyte abnormalities can occur with nonsignificant blood glucose elevations in SGLT2I-treated patients. Additional risk factors for eDKA include prolonged fasting, major illness, large weight loss, and reductions in insulin doses.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Banakh et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: